⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.
PRMT6–FOXG1–Mitophagy Axis in Cochlear Aging
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-09 — Cell-Type-Specific Calibration of Mitochondrial Ubiquitination in Stem Cell Fate Decisions.: cross-connection with pink1-parkin-mitophagy: Both frame selective mitophagy as regulated by tissue-specific post-translational modifications (ubiquitination via PINK1/Parkin; arginine methylation via PRMT6→FOXG1), converging on mitochondrial quality-control failure as a cell-type-tunable aging driver. (novelty: 3)
- 2026-07-01 — Lysine methyltransferase methyltransferase-like 13 regulates bone marrow mesenchymal stem cells osteo-adipogenic differentiation and senescence in osteoporosis via the Foxa1/HES-1 axis.: cross-connection with mettl13-foxa1-hes1-axis: Both implicate methyltransferase-driven degradation/regulation of a forkhead transcription factor (Foxa1, FOXG1) as an upstream node driving tissue-specific senescence — a recurring motif linking methylation writers to senescence programs. (novelty: 3)
- 2026-08-12 — PRMT6 drives hearing loss by promoting asymmetric arginine dimethylation-mediated FOXG1 degradation and suppressing mitophagy.: Foundational mouse + HEI-OC1 study: PRMT6 asymmetrically dimethylates FOXG1, driving its degradation and suppressing mitophagy in D-gal-induced cochlear aging; PRMT6 inhibition/silencing restores mitophagy and reverses senescence and hearing-loss phenotypes. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
PRMT6 drives hearing loss by promoting asymmetric arginine dimethylation-mediated FOXG1 degradation and suppressing mitophagy.
12-aug-2026
novelty 3
per-area 3
strengthens